Additionally, the ability of HDAC6 inhibitors to protect against chemotherapy-induced peripheral neuropathy further underscores their potential to improve patient quality of life irrespective of HDAC6-mediated anticancer activity. Here, HDAC6 is linked to peripheral neuropathy.